Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment
Authors
Keywords
-
Journal
Therapeutic Advances in Chronic Disease
Volume 9, Issue 5, Pages 111-119
Publisher
SAGE Publications
Online
2018-03-19
DOI
10.1177/2040622318759282
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment
- (2018) Jaehwan Kim et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Autoantigens ADAMTSL5 and LL37 are significantly upregulated in active Psoriasis and localized with keratinocytes, dendritic cells and other leukocytes
- (2017) Judilyn Fuentes-Duculan et al. EXPERIMENTAL DERMATOLOGY
- Psoriasis pathogenesis and the development of novel targeted immune therapies
- (2017) Jason E. Hawkes et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Psoriasis and comorbid diseases
- (2017) Junko Takeshita et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
- (2017) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
- (2017) Kristian Reich et al. LANCET
- Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
- (2017) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target
- (2017) Satveer K. Mahil et al. Science Translational Medicine
- The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function
- (2017) Carolina M. Pfaff et al. Scientific Reports
- IL-23 induced in keratinocytes by endogenous TLR4 ligands polarizes dendritic cells to drive IL-22 responses to skin immunization
- (2016) Juhan Yoon et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The Immunopathogenesis of Psoriasis
- (2015) Jaehwan Kim et al. DERMATOLOGIC CLINICS
- Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial
- (2015) James G. Krueger et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- An autoimmune “attack” on melanocytes triggers psoriasis and cellular hyperplasia
- (2015) James G. Krueger JOURNAL OF EXPERIMENTAL MEDICINE
- Melanocyte antigen triggers autoimmunity in human psoriasis
- (2015) Akiko Arakawa et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Immunology of Psoriasis
- (2014) Michelle A. Lowes et al. Annual Review of Immunology
- Alarmin Function of Cathelicidin Antimicrobial Peptide LL37 through IL-36γ Induction in Human Epidermal Keratinocytes
- (2014) Na Li et al. JOURNAL OF IMMUNOLOGY
- IL-19 Is a Component of the Pathogenetic IL-23/IL-17 Cascade in Psoriasis
- (2014) Ellen Witte et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Psoriasis prevalence among adults in the United States
- (2014) Tara D. Rachakonda et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- IL-17 Induces an Expanded Range of Downstream Genes in Reconstituted Human Epidermis Model
- (2014) Andrea Chiricozzi et al. PLoS One
- IL-17 and TNF Synergistically Modulate Cytokine Expression while Suppressing Melanogenesis: Potential Relevance to Psoriasis
- (2013) Claire Q.F. Wang et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- IL-17 and IL-22 enhance skin inflammation by stimulating the secretion of IL-1β by keratinocytes via the ROS-NLRP3-caspase-1 pathway
- (2011) Kyung-Ah Cho et al. INTERNATIONAL IMMUNOLOGY
- Inter-Regulation of Th17 Cytokines and the IL-36 Cytokines In Vitro and In Vivo: Implications in Psoriasis Pathogenesis
- (2011) Yijun Carrier et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Overrepresentation of IL-17A and IL-22 Producing CD8 T Cells in Lesional Skin Suggests Their Involvement in the Pathogenesis of Psoriasis
- (2010) Pieter C. M. Res et al. PLoS One
- IL-17 and Th17 Cells
- (2009) Thomas Korn et al. Annual Review of Immunology
- A Central Role for Transcription Factor C/EBP- in Regulating CD1d Gene Expression in Human Keratinocytes
- (2009) H. Sikder et al. JOURNAL OF IMMUNOLOGY
- Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: Implications for Psoriasis Pathogenesis
- (2009) Erin G. Harper et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis
- (2009) Antonella Di Cesare et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Resident and “Inflammatory” Dendritic Cells in Human Skin
- (2008) Lisa C. Zaba et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started